Journal of Current Glaucoma Practice

Register      Login

VOLUME 12 , ISSUE 3 ( September-December, 2018 ) > List of Articles


Pathogenesis of Uveitic Glaucoma

Dimitrios Kalogeropoulos, Velota CT Sung

Keywords : Glaucoma, Intraocular pressure, Ocular hypertension/hypotony, Ocular inflammation, Uveitis, Uveitic glaucoma

Citation Information : Kalogeropoulos D, Sung VC. Pathogenesis of Uveitic Glaucoma. J Curr Glaucoma Pract 2018; 12 (3):125-138.

DOI: 10.5005/jp-journals-10078-1236

License: CC BY-NC 4.0

Published Online: 01-12-2018

Copyright Statement:  Copyright © 2018; The Author(s).


Uveitic glaucoma consists one of the most serious complications of intraocular inflammation and, despite its rarity, is considered as one of the leading causes of preventable loss of vision worldwide. It has been associated with a wide spectrum of inflammatory diseases, but its pathogenesis is still not fully comprehended. It appears that the type of inflammation, the steroid-response and the anatomical alterations of the anterior chamber play a pivotal role. To our knowledge, the mechanisms may be both acute and chronic. The main targets of the treatment are to control the inflammation and reduce the intraocular pressure (IOP). The management of glaucoma associated with uveitis remains an extremely challenging condition for ophthalmologists. The successful treatment of uveitic glaucoma is inextricably correlated with prompt and immediate therapeutic decisions. Very often a solid collaboration between clinicians from different specialties may be required for treating the underlying disease. Further understanding of its pathogenesis can indicate therapeutic targets and may lead to the development of new and more efficient therapeutic approaches. New glaucoma surgical modalities may ameliorate the prognosis after surgical intervention, but this calls for further evaluation. This study aims to highlight the complexity of uveitic glaucoma analyzing the main pathogenetic mechanisms and the correlations with the inflammatory response.

PDF Share
  1. Siddique SS, Suelves AM, Baheti U, et al. Glaucoma and uveitis. Surv Ophthalmol 2013;58:1-10.
  2. Neri P, Azuara-Blanco A, Forrester JV. Incidence of glaucoma in patients with uveitis. J Glaucoma 2004;13:461-465.
  3. Moorthy R, Mermoud A, Baerveldt G, et al. Glaucoma associated with uveitis. Surv Ophthalmol 1997;41:361-394.
  4. Baneke AJ, Lim KS, Stanford M. The Pathogenesis of Raised Intraocular Pressure in Uveitis. Curr Eye Res. 2016; 41(2):137-149.
  5. Sng CC, Ang M, Barton K. Uveitis and glaucoma: new insights in the pathogenesis and treatment. Prog Brain Res. 2015;221:243-269.
  6. Muñoz-Negrete FJ, Moreno-Montañés J, Hernández-Martínez P, et al. Current Approach in the Diagnosis and Management of Uveitic Glaucoma. Biomed Res Int. 2015;2015:742792.
  7. Toris CB, Pederson JE. Aqueous humor dynamics in experimental iridocyclitis. Invest. Ophthalmol. Vis. Sci. 1987;28 (3): 477-481.
  8. Kok H, Barton K. Uveitic glaucoma. Ophthalmol Clin North Am. 2002;15(3):375-387.
  9. Herbert HM, Viswanathan A, Jackson H, et al. Risk factors for elevated intraocular pressure in uveitis. J. Glaucoma 2004;13(2):96-99.
  10. Kanda T, Shibata M, Taguchi M, Herbert HM, Viswanathan A, Jackson H, et al. Prevalence and aetiology of ocular hypertension in acute and chronic uveitis. Br J Ophthalmol. 2014;98: 932-936.
  11. Herbert HM, Viswanathan A, Jackson H, et al. Risk factors for elevated intraocular pressure in uveitis. J Glaucoma. 2004;13(2):96-99.
  12. Neri P, Azuara-Blanco A, Forrester JV. Incidence of glaucoma in patients with uveitis. J Glaucoma. 2004;13(6):461-465.
  13. Sen HN, Drye LT, Goldstein DA, et al. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Hypotony in patients with uveitis: the multicenter uveitis steroid treatment (MUST) trial. Ocul Immunol Inflamm. 2012;20(2):104-112.
  14. Aman R, Engelhard SB, Bajwa A, et al. Ocular hypertension and hypotony as determinates of outcomes in uveitis. Clin Ophthalmol. 2015 Dec 7;9:2291-98.
  15. Toris CB, Pederson JE. Aqueous humor dynamics in experimental iridocyclitis. Invest Ophthalmol Vis Sci 1987;28:477-481.
  16. Bill A. Aqueous humor dynamics in monkeys (Macaca irus and Cercopithecus ethiops). Exp Eye Res 1971;11:195-206.
  17. Mermoud A, Baerveldt G, Mickler DS, et al. Animal model for uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol 1994;232:553-560.
  18. Bill A, Phillips CI. Uveoscleral drainage of aqueous humour in human eyes. Exp Eye Res 1971;12:275-281.
  19. Toris C, Camras C, Yablonski M. Effects of PhXA41, a new prostaglandin F2a analogue, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100:1297-1304.
  20. Toris CB, Yablonski ME, Wang Y-L, et al. Aqueous humor dynamics in the aging human eye. Am J Ophthalmol 1999;127:407-412.
  21. Toris CB, Koepsell SA, Yablonski ME, et al. Aqueous humor dynamics in ocular hypertensive patients. J Glaucoma 2002;11:253-258.
  22. Howes EJ, Cruse VK. The structural basis of altered vascular permeability following intraocular inflammation. Arch Ophthalmol 1978;96:1668-1676.
  23. Horsley M, Chen T. The use of prostaglandin analogs in the uveitic patient. Semin Ophthalmol 2011;26:285-289.
  24. Eakins K, Whitelocke R, Bennett A, et al. Prostaglandin-like activity in ocular inflammation. Br J Med 1972;3:452-453.
  25. Herbort C, Mermoud A, Schnyder C, et al. Antiinflammatory effect of diclofenac drops after argon laser trabeculoplasty. Arch Ophthalmol 1993;111:481-483.
  26. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 2008;53: S107-S120.
  27. Ladas JG, Yu F, Loo R, et al. Relationship between aqueous humor protein level and outflow facility in patients with uveitis. Invest Ophthalmol Vis Sci 2001;42:2584-2588.
  28. Epstein DL, Hashimoto JM, Grant WM. Serum obstruction of aqueous outflow in enucleated eyes. Am J Ophthalmol 1978;86:101-105.
  29. Peretz WL, Tomasi T. Aqueous humor proteins in uveitis. Immunoelectrophoretic and gel diffusion studies on normal and pathological human aqueous humor. Arch Ophthalmol 1961;65:20-23.
  30. Epstein DL, Jedziniak JA, Grant WM. Obstruction of aqueous outflow by lens particles and by heavy-molecularweight soluble lens proteins. Invest Ophthalmol Vis Sci 1978;17:272-277.
  31. Altamirano D, Mermoud A, Pittet N, et al. Aqueous humor analysis after Nd:YAG laser capsulotomy with the laser flarecell meter. J Cataract Refract Surg 1992;18:554-558.
  32. Ge J, Wand M, Chiang R, et al. Longterm effect of Nd:YAG laser posterior capsulotomy on intraocular pressure. Arch Ophthalmol 2000;118: 1334-1337.
  33. Cohen RG, Wu HK, Schuman JS. Glaucoma with inflammatory precipitates on the trabecular meshwork: a report of Grant's syndrome with ultrasound biomicroscopy of precipitates. J Glaucoma 1996;5:266-270.
  34. Fiore PM, Melamed S, Epstein DL. Trabecular precipitates and elevated intraocular pressure following argon laser trabeculoplasty. Ophthalmic Surg 1989;20:697-701.
  35. Richardson TM, Hutchinson BT, Grant WM. The outflow tract in pigmentary glaucoma: a light and electron microscopic study. Arch Ophthalmol 1977;95:1015-1025.
  36. Hogan MJ, Kimura SJ, Thygeson P. Pathology of herpes simplex kerato-iritis. Trans Am Ophthalmol Soc 1963;61(37): 75-99.
  37. Townsend WM, Kaufman HE. Pathogenesis of glaucoma and endothelial changes in herpetic kerato-uveitis in rabbits. Am J Ophthalmol 1971;71:904-910.
  38. Horai R, Caspi RR. Cytokines in autoimmune uveitis. J Interferon Cytokine Res 2011;31:733-744.
  39. Murray P, Clay C, Mappin C, et al. Molecular analysis of resolving immune responses in uveitis. Clin Exp Immunol 1999;117:455-461.
  40. Murphy CC, Duncan L, Forrester JV, et al. Systemic CD4(+) T cell phenotype and activation status in intermediate uveitis. Br J Ophthalmol 2004;88:412-416.
  41. Deschenes J, Char D, Kaleta S. Activated T lymphocytes in uveitis. Br J Ophthalmol 1988;72:83-87.
  42. Norose K, Yano A, Wang XC, et al. Dominance of activated T cells and interleukin-6 in aqueous humor in Vogt-Koyanagi- Harada disease. Invest Ophthalmol Vis Sci.1994; 35:33-39.
  43. Verma MJ, Lloyd A, Rager H, et al. Chemokines in acute anterior uveitis. Curr Eye Res. 1997;16:1202-1208.
  44. Abu El-Asrar AM, St ruyf S, Descamps FJ, et al. Chemokines and gelatinases in the aqueous humor of patients with active uveitis. Am J Ophthalmol. 2004;138: 401-411.
  45. Sijssens KM, Rijkers GT, Rothova A, et al. Cytokines, chemokines and soluble adhesion molecules in aqueous humor of children with uveitis. Exp Eye Res. 2007;85:443-449.
  46. Abu El-Asrar AM, Struyf S, Kangave D, et al. Cytokine and CXC chemokine expression patterns in aqueous humor of patients with presumed tuberculous uveitis. Cytokine. 2012;59:377-381.
  47. Ohira S, Inoue T, Iwao K, et al.. Factors Influencing Aqueous Proinflammatory Cytokines and Growth Factors in Uveitic Glaucoma. PLoS One. 2016 Jan 15;11(1): e0147080.
  48. Weinreb RN, Sandman R, Ryder MI, et al. Angiotensinconverting enzyme activity in human aqueous humor. Arch Ophthalmol 1985;103:34-36.
  49. Shah GB, Sharma S, Mehta AA, et al. Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. J Cardiovasc Pharmacol 2000;36:169-175.
  50. Mehta A, Iyer L, Parmar S, et al. Oculohypotensive effect of perindopril in acute and chronic models of glaucoma in rabbits. Can J Physiol Pharmacol 2010;88:595-600.
  51. Hirooka K, Shiraga F. Potential role for angiotensin converting enzyme inhibitors in the treatment of glaucoma. Clin Ophthalmol 2007;1:217-223.
  52. Rao PV, Deng PF, Kumar J, et al. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci 2001;42:1029-1037.
  53. Oguz E, Alasehirli B, Pehlivan Y, et al. Association between Rho-kinase (ROCK2) gene polymorphisms and Behçet's disease. Transl Res 2012; 160:428-434.
  54. Rao NA, Wu GS. Free radical mediated photoreceptor damage in uveitis. Prog Retin Eye Res 2000;19:41-68.
  55. Sorkhabi R, Ghorbanihaghjo A, Javadzadeh A, Rashtchizadeh N, Moharrery M. Oxidative DNA damage and total antioxidant status in glaucoma patients. Mol Vis 2011;17:41-46.
  56. Oshida E, Matsumoto Y, Arai K. Free radicals in the aqueous humor of patients with glaucoma. Clin Ophthalmol 2010;4:653-660.
  57. Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye (Lond) 2006;20: 407-416.
  58. Razeghinejad MR, Katz LJ. Steroid-induced iatrogenic glaucoma. Ophthalmic Res 2012;47:66-80.
  59. Busquets M, Zdrale N, Nairn J, et al. Intraocular pressure changes after removal of sub-tenon's triamcinolone acetonide depot. Retinal Physician. 2010;7:45-48.
  60. Yamashita T, Kodama Y, Tanaka M, et al. Steroid-induced glaucoma in children with acute lymphoblastic leukemia: a possible complication. J Glaucoma. 2010;19:188-890.
  61. Ang M, Ho CL, Tan D, et al. Severe vernal keratoconjunctivitis requiring trabeculectomy with mitomycin C for corticosteroid- induced glaucoma. Clin Experiment Ophthalmol. 2012 May-Jun;40(4): e149-155.
  62. Shrestha S, Thapa M, Shah DN. Pattern of intraocular pressure fluctuation in uveitic eyes treated with corticosteroids. Ocul Immunol Inflamm. 2014 Apr;22(2):110-115.
  63. Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin 1992;10:505-512.
  64. Yue BY. The extracellular matrix and its modulation in the trabecular meshwork. Surv Ophthalmol 1996;40:379-390.
  65. Francois J. Corticosteroid glaucoma. Ann Ophthalmol 1977;9:1075-1080.
  66. Fautsch MP, Bahler CK, Jewison DJ, et al. Recombinant TIGR/ MYOC increases outflow resistance in the human anterior segment. Invest Ophthalmol Vis Sci 2000;41:4163-4168.
  67. Lo WR. Tissue differential microarray analysis of dexamethasone induction reveals potential mechanisms of steroid glaucoma. Invest Ophthalmol Vis Sci 2003;44: 473-485.
  68. Jap A, Chee SP. Viral anterior uveitis. Curr Opin Ophthalmol. 2011 Nov;22(6):483-488.
  69. Takase H, Kubono R, Terada Y, et al. Comparison of the ocular characteristics of anterior uveitis caused by herpes simplex virus, varicella-zoster virus, and cytomegalovirus. Jpn J Ophthalmol. 2014 Nov;58(6):473-482.
  70. Sungur GK, Hazirolan D, Yalvac IS, et al. Incidence and prognosis of ocular hypertension secondary to viral uveitis. Int Ophthalmol. 2010 Apr;30(2):191-194.
  71. Varkey JB, Shantha JG, Crozier I, et al. Persistence of Ebola Virus in Ocular Fluid during Convalescence. N Engl J Med. 2015 Jun 18;372(25):2423-2427.
  72. Chee SP, Jap A. Presumed fuchs heterochromic iridocyclitis and Posner-Schlossman syndrome: comparison of cytomegalovirus- positive and negative eyes. Am J Ophthalmol. 2008 Dec;146(6):883-889.
  73. Chee SP, Bacsal K, Jap A, et al. Clinical features of cytomegalovirus anterior uveitis in immunocompetent patients. Am J Ophthalmol. 2008 May;145(5):834-840.
  74. Sung VCT, Barton K. Management of inflammatory glaucomas. Current Opinion in Ophthalmology. Curr Opin Ophthalmol. 2004 Apr;15(2):136-140.
  75. Shimizu A, Maruyama K, Yokoyama K, et al. Characteristics of uveitic glaucoma and evaluation of its surgical treatment. Clin Ophthalmol. 2014 Nov 26;8:2383-2389.
  76. Iverson SM, Bhardwaj N, Shi W et al. Surgical outcomes of inflammatory glaucoma: a comparison of trabeculectomy and glaucoma-drainage-device implantation. Japanese Journal of Ophthalmology. Jpn J Ophthalmol. 2015 May;59(3): 179-186.
  77. Allingham RR, Damji K, Freedman S, et al. editors. Shields textbook of glaucoma. 5th ed. Baltimore: Lippincott Williams and Wilkins; 2005. Steroid induced glaucoma.
  78. Kimura SJ, Hogan MJ, Thygeson P. Fuchs’ syndrome of heterochromic cyclitis. AMA Arch Ophthalmol. 1955;54: 179-186.
  79. Jones NP. Fuch's hetrochromic uveitis: An update. Surv Opthalmol. 1993;37:253-272.
  80. Birnbaum AD, Tessler HH, Schultz KL, et al. Epidemiologic relationship between fuchs heterochromic iridocyclitis and the United States rubella vaccination program. Am J Ophthalmol. 2007;144:424-428.
  81. Quentin CD, Reiber H. Fuchs heterochromic cyclitis: rubella virus antibodies and genome in aqueous humor. Am J Ophthalmol. 2004;138:46-54.
  82. Allingham RR. Glaucoma due to intraocular inflammation. In: Epstein DL, Schuman JS, editors. Chandler and Grant's glaucoma. 4th ed. Baltimore, MD: Williams and Willkins;
  83. p. 376-394.
  84. Hong C, Song KY. Effect of apraclonidine hydrochloride on the attack of Posner Schlossman syndrome. Korean J Ophthalmol. 1993;7:28-33.
  85. Yamamoto S, Pavan-Langston D, Tada R, et al. Possible role of herpes simplex virus in the origin of Posner Schlossman syndrome. Am J Ophthalmol. 1995;119:796-798.
  86. Bloch-Michel E, Dussaix E, Sibillat M, et al. [Posner- Schlossmann syndrome. A cytomegalovirus infection?]. Bull Soc Ophtalmol Fr. 1988;88:75-76.
  87. Hirose S, Ohno S, Matsuda H. HLA Bw 54 and glaucomocyclitic crisis. Arch Ophthalmol. 1985;103:1837-1839.
  88. Knox DL. Glaucomatocyclitic crises and systemic disease: peptic ulcer, other gastrointestinal disorders, allergy and stress. Trans Am Ophthalmol Soc. 1988;86:473-495.
  89. Pillai CT, Dua HS, Azuara-Blanco A, et al. Evaluation of corneal endothelium and keratic precipitates by specular microscopy in anterior uveitis. Br J Ophthalmol. 2000;84:1367–1371.
  90. Matsuda K, Izawa Y, Mishima S. Prostaglandins and glaucomatocyclitic crisis. Jpn J Ophthalmol. 1975;19:368-375.
  91. Miserocchi E, Waheed NK, Dios E, et al. Visual outcome in herpes simplex virus and varicella zoster virus uveitis: a clinical evaluation and comparison. Ophthalmology. 2002;109:1532-1537.
  92. Karbassi M, Raizman MB, Schuman JS. Herpes zoster ophthalmicus. Surv Ophthalmol. 1992;36:395-410.
  93. Falcon MG, Williams HP. Herpes simplex keratouveitis and glaucoma. Trans Ophthalmol Soc UK. 1978;98:101-104.
  94. Liesegang TJ. Classification of herpes simplex virus keratitis and anterior uveitis. Cornea. 1999;18:127-143
  95. Uchoa UB, Rezende RA, Carrasco MA, et al. Long-term acyclovir use to prevent recurrent ocular herpes simplex virus infection. Arch Ophthalmol. 2003;121:1702-1704.
  96. Kanski JJ, Shun-Shin GA. Systemic uveitis syndromes in childhood: an analysis of 340 cases. Ophthalmology. 1984; 91:1247-1252.
  97. Karbassi M, Raizman MB, Schuman JS. Herpes zoster ophthalmicus. Surv Ophthalmol. 1992;36:395-410.
  98. Wolf MD, Lichter PR, Ragsdale CG. Prognostic factors in the uveitis of juvenile rheumatoid arthritis. Ophthalmology. 1987;94:1242-1248.
  99. Foster CS, Havrlikova K, Baltatzis S, et al. Secondary glaucoma in patients with juvenile rheumatoid arthritis--associated iridocyclitis. Acta Ophthalmol Scand. 2000;78:576-579.
  100. Bodh SA, Kumar V, Raina UK, Ghosh B, et al. Inflammatory glaucoma. Oman J Ophthalmol. 2011 Jan;4(1):3-9.
  101. Peng S, Sun X, Sun M. Adalimumab for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017 Aug 24;377(8):789.
  102. Ramanan AV, Dick AD, Beresford MW. Adalimumab for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017 Aug 24;377(8):789-790.
  103. Correll CK, Bullock DR, Cafferty RM, et al. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis. Clin Rheumatol. 2017 Nov 4.
  104. Balevic SJ, Rabinovich CE. Profile of adalimumab and its potential in the treatment of uveitis. Drug Des Devel Ther. 2016 Sep 19;10:2997-3003.
  105. Gouveia EB, Elmann D, Morales MS. Ankylosing spondylitis and uveitis: overview. Rev Bras Reumatol. 2012 Oct;52(5):742-756.
  106. Monnet D, Breban M, Hudry C, et al. Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases. Ophthalmology. 2004 Apr. 111(4):802-809.
  107. Chang JH, McCluskey PJ, Wakefield D. Acute anterior uveitis and HLA-B27. Surv Ophthalmol. 2005 Jul-Aug. 50(4):364-88.
  108. McCannel CA, Holland GN, Helm CJ, et al. Causes of uveitis in the general practice of ophthalmology. Am J Ophthalmol 1996;121(1):35-46.
  109. Ladas JG. Laser flare-cell photometry: methodology and clinical applications. Surv Ophthalmo 2005;50(1):27-47.
  110. Rodriguez A, Akova YA, Pedroza-Seres M, et al. Posterior segment ocular manifestations in patients with HLA-B27- associated uveitis. Ophthalmology 1994; 101(7):1267-1274
  111. Bonfiolli AA, Orefice F. Sarcoidosis. Semin Ophthalmol. 2005;20:177-182.
  112. Francoise J. Corticosteroid glaucoma. Ophthalmologica. 1984;188:76.
  113. Shimizu A, Maruyama K, Yokoyama Y, et al. Characteristics of uveitic glaucoma and evaluation of its surgical treatment. Clin Ophthalmol. 2014 Nov 26;8:2383-2389.
  114. Paovic J, Paovic P, Sredovic V, et al. Clinical Manifestations, Complications and Treatment of Ocular Sarcoidosis: Correlation between Visual Efficiency and Macular Edema as Seen on Optical Coherence Tomography. Semin Ophthalmol. 2016 Sep 14:1-8.
  115. Grant WM. Late glaucoma after interstitial keratitis. Am J Ophthalmol. 1975;79:87-91.
  116. Tsukahara S. Secondary glaucoma due to inactive congenital syphilitic interstitial keratitis. Ophthalmologica. 1977;174:188-194.
  117. Andreoli CM, Foster CS. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2006 Spring. 46(2):111-122.
  118. Yang P, Ren Y, Li B, et al. Clinical characteristics of Vogt- Koyanagi-Harada syndrome in Chinese patients. Ophthalmology. 2007 Mar. 114(3):606-614.
  119. da Silva FT, Damico FM, Marin ML, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: considerations on the different disease categories. Am J Ophthalmol. 2009 Feb. 147(2):339-345.e5.
  120. Rajendram R, Evans M, Rao NA. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2005 Spring. 45(2):115-134.
  121. Usui Y, Goto H, Sakai J, et al. Presumed Vogt-Koyanagi- Harada disease with unilateral ocular involvement: report of three cases. Graefes Arch Clin Exp Ophthalmol. 2009 Aug. 247(8):1127-1132.
  122. Chandler PM, Grant WM. Philadelphia: Lea and Febiger;
  123. Lectures on glaucoma; p. 257.
  124. Roth M, Simon RJ. Glaucoma associated with precipitates on trabecular meshwork. Ophthalmology. 1979;86:1613-1619.
  125. Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol. 1976;60:163-191.
  126. McGavin DD, Williamson J, Forrester JV, et al. Episcleritis and scleritis: A study of their clinical manifestations and association with rheumatoid arthritis. Br J Ophthalmol. 1976;60:192-226.
  127. Chen CJ, Harisdangkul V, Parker L. Transient glaucoma associated with anterior diffuse scleritis in relapsing polychondritis. Glaucoma.
  128. Watson PG, Bovey E. Anterior segment fluorescein angiography in the diagnosis of scleral inflammation. Ophthalmology. 1985;92:1-11.
  129. Zhang L, Hood CT, Vrabec JP, et al. Mechanisms for in-thebag uveitis-glaucomahyphema syndrome. Journal of Cataract and Refractive Surgery, 2014;40(3):490-492.
  130. Kulkarni A, Barton K. Uveitic glaucoma. in Glaucoma. Medical Diagnosis & Therapy, Shaarwy TM, Sherwood MB, Hitching RA, Crowston JG. Crowston, Eds., pp. 410–424, Elsevier Saunders, London, UK, 2015.
  131. Moore DB, Jaffe GJ, Asrani S. Retinal nerve fiber layer thickness measurements: uveitis, a major confounding factor. Ophthalmology. 2015 Mar;122(3):511-517.
  132. Asrani S, Moore DB, Jaffe GJ. Paradoxical changes of retinal nerve fiber layer thickness in uveitic glaucoma. JAMA Ophthalmol. 2014 Jul;132(7):877-880.
  133. Din NM, Taylor SR, Isa H et al. Evaluation of retinal nerve fiber layer thickness in eyes with hypertensive uveitis. JAMA Ophthalmol. 2014 Jul;132(7):859-865.
  134. Fardeau C, Champion E, Massamba N, et al. Uveitic macular edema. Eye (Lond). 2016 Oct;30(10):1277-1292.
  135. Lopilly Park HY, Jung KI, et al. Serial intracameral visualization of the Ahmed glaucoma valve tube by anterior segment optical coherence tomography. Eye (Lond). 2012 Sep;26(9):1256-1262.
  136. Ciancaglini M, Carpineto P, Agnifili L et al. Filtering bleb functionality: a clinical, anterior segment optical coherence tomography and in vivo confocal microscopy study. J Glaucoma. 2008 Jun-Jul;17(4):308-317.
  137. Mastropasqua R, Fasanella V, Agnifili L, et al. Anterior segment optical coherence tomography imaging of conjunctival filtering blebs after glaucoma surgery. Biomed Res Int. 2014;2014:610623.
  138. Min SH, Lee TI, Chung YS, et al. Transforming growth factor-beta levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes. Korean J Ophthalmol. 2006 Sep;20(3):162-165.
  139. Pfeiffer N, Voykov B, Renieri G, et al. First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-â2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery. PLoS One. 2017 Nov 30;12(11): e0188899.
  140. Tripathi RC, Li J, Chan WF, et al. Aqueous humor in glaumatous eyes contains an increased level of TGF-â2. Exp Eye Res 1994;9:723-728.
  141. Armaly MF: The heritable nature of dexamethasone-induced ocular hypertension. Arch Ophthalmol 1966;75:32-35.
  142. Patelska B, Greenfield DS, Liebmann JM, et al. Latanoprost for uncontrolled glaucoma in a compassionate case protocol. Am J Ophthalmol 1997;124:279-286.
  143. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with Latanoprost use: experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998;105:263-268.
  144. Smith SL, Pruitt CA, Sine CS, et al. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand 1999;77: 668-672.
  145. Callanan D, Fellman RL, Savage JA. Latanoprost-associated cystoid macular edema. Am J Ophthalmol 1998, 126:134-135.
  146. Heier JS, Steinert RF, Frederick AR. Cystoid macular edema associated with Latanoprost use. Arch Ophthalmol 1998; 116: 680-682
  147. Ayyala RS, Cruz DA, Margo CE, et al. Cystoid macular edema associated with latanoprost.
  148. Kaufman HE, Varnell ED, Thompson HW. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am J Ophthalmol 1999;127:531-536.
  149. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol 1999;127:602-604.
  150. Sponsel WE, Paris G, Trigo Y, et al. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal antiinflammatory therapy. Am J Ophthalmol 2002;133:11-18.
  151. Kashiwagi K, Tsukahara S. Effect of non-steroidal antiinflammatory ophthalmic solution on intraocular pressure reduction by latanoprost. Br J Ophthalmol 2003;87: 297-301.
  152. Broadway DC, Bates AK, Lightman SL, et al. The importance of cellular changes in the conjunctiva of patients with uveitic glaucoma undergoing trabeculectomy. Eye 1993;7: 495-501.
  153. Stavrou P, Murray PI. Long-term follow-up of trabeculectomy without antimetabolites in patients with uveitis. Am J Ophthalmol 1999;128:434-439.
  154. Ceballos EM, Beck AD, Lynn MJ. Trabeculectomy with antiproliferative agents in uveitic glaucoma. J Glaucoma 2002;11:189-196
  155. Prata JA, Neves RA, Minckler DS, et al. Trabeculectomy with Mitomycin C in glaucoma associated with uveitis. Ophthalmic Surg 1994;25:616-620.
  156. Wright MM, McGehee RF, Pederson JE. Intraoperative mitomycin- C for glaucoma associated with ocular inflammation. Ophthalmic Surg Lasers 1997;28:370-376.
  157. Towler HMA, Bates AK, Broadway DC, et al. Primary trabeculectomy with 5-fluorouracil for glaucoma secondary to uveitis. Ocular Immunol and Inflamm 1995;3: 163-170.
  158. Towler HM, McCluskey P, Shaer B, et al. Long-term followup of trabeculectomy with intraoperative 5- fluorouracil for uveitis-related glaucoma. Ophthalmology 2000;107:1822-1828.
  159. Jampel HD, Jabs DA, Quigley HA. Trabeculectomy with 5-fluorouracil for adult inflammatory glaucoma. Am J Ophthalmol 1990;109:168-173.
  160. Patitsas CJ, Rockwood EJ, Meisler DM, et al. Glaucoma filtering surgery with postoperative 5-Fluorouracil in patients with intraocular inflammatory disease. Ophthalmology 1992;99:594-599.
  161. Molteno AC, Sayawat N, Herbison P. Otago glaucoma surgery outcome study: long-term results of uveitis with secondary glaucoma drained by Molteno implants. Ophthalmology 2001;108:605-613.
  162. Da Mata A, Burk SE, Netland PA, et al.. Management of uveitic glaucoma with Ahmed glaucoma valve implantation. Ophthalmology 1999;106:2168-2172.
  163. Ceballos EM, Parrish RK, Schiffman JC. Outcome of Baerveldt glaucoma drainage implants for the treatment of uveitic glaucoma. Ophthalmology 2002;109:2256-2260.
  164. Murphy CC, Burnett CA, Spry PG, et al. A two centre study of the dose-response relation for transscleral diode laser cyclophotocoagulation in refractory glaucoma. Br J Ophthalmol 2003;87:1252-1257.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.